Inflammation and Vasculitis Related to Brolucizumab
Abstract
:1. Introduction
2. Material and Methods
2.1. Eyes, Injections and Imaging
2.2. Statistical Analyses
3. Results
3.1. Case Description
3.2. Case with Retinal Vasculitis and Retinal Arterial Occlusion
3.3. Statistical Analyses and Relevance
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Iyer, P.G.; Peden, M.C.; Suñer, I.J.; Patel, N.; Dubovy, S.R.; Albini, T.A. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study. Am. J. Ophthalmol. Case Rep. 2020, 20, 100989. [Google Scholar] [CrossRef]
- Wykoff, C.C.; Matsumoto, H.; Barakat, M.R.; Karcher, H.; Lozama, A.; Mayhook, A.; Oshagbemi, O.A.; Zorina, O.; Hassan, T.S.; Khanani, A.M.; et al. Retinal vasculitis or vascular occlusion after brolucizumab for neovascular age-related macular degeneration: A Systematic Review of Real-World Evidence. Retina 2023, 43, 1051–1063. [Google Scholar] [CrossRef] [PubMed]
- Markham, A. Brolucizumab: First Approval. Drugs 2019, 79, 1997–2000. [Google Scholar] [CrossRef] [PubMed]
- Dugel, P.U.; Koh, A.; Ogura, Y.; Jaffe, G.J.; Schmidt-Erfurth, U.; Brown, D.M.; Gomes, A.V.; Warburton, J.; Weichselberger, A.; Holz, F.G.; et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2020, 127, 72–84. [Google Scholar] [CrossRef] [PubMed]
- Garweg, J.G. A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE). Klin. Monatsblatter Augenheilkd. 2020, 237, 450–453. [Google Scholar] [CrossRef]
- Eissing, T.; Stewart, M.W.; Qian, C.X.; Rittenhouse, K.D. Durability of VEGF Suppression with Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes. Transl. Vis. Sci. Technol. 2021, 10, 9. [Google Scholar] [CrossRef]
- Spaide, R.F. Antivascular Endothelial Growth Factor Dosing and Expected Acuity Outcome at 1 Year. Retina 2021, 41, 1153–1163. [Google Scholar] [CrossRef]
- Mones, J.; Singh, R.P.; Bandello, F.; Souied, E.; Liu, X.; Gale, R. Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. Ophthalmologica 2020, 243, 1–8. [Google Scholar] [CrossRef]
- Tomas, R.O.; Campos, A.; Oliveira, N.; Soares, P.; Sousa, J.P. Preserving visual acuity: A compelling 12-year case study of controlling neovascular age-related macular degeneration. BMC Ophthalmol. 2024, 24, 123. [Google Scholar] [CrossRef]
- Motevasseli, T.; Mohammadi, S.; Abdi, F.; Freeman, W.R. Side Effects of Brolucizumab. J. Ophthalmic Vis. Res. 2021, 16, 670–675. [Google Scholar] [CrossRef]
- Fonollosa, A.; Gallego-Pinazo, R.; Sararols, L.; Adán, A.; López-Gálvez, M.; Figueroa, M.S. Guidance on brolucizumab management recommendations. Arch. Soc. Esp. Oftalmol. (Engl. Ed.) 2022, 97, 626–638. [Google Scholar] [CrossRef]
- Rosenfeld, P.J.; Browning, D.J. Is This a 737 Max Moment for Brolucizumab? Am. J. Ophthalmol. 2020, 216, A7–A8. [Google Scholar] [CrossRef]
- Baumal, C.R.; Spaide, R.F.; Vajzovic, L.; Freund, K.B.; Walter, S.D.; John, V.; Rich, R.; Chaudhry, N.; Lakhanpal, R.R.; Oellers, P.R.; et al. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology 2020, 127, 1345–1359. [Google Scholar] [CrossRef]
- Witkin, A.J.; Hahn, P.; Murray, T.G.; Arevalo, J.F.; Blinder, K.J.; Choudhry, N.; Emerson, G.G.; Goldberg, R.A.; Kim, S.J.; Pearlman, J.; et al. Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. J. Vitreoretin. Dis. 2020, 4, 269–279. [Google Scholar] [CrossRef] [PubMed]
- Kilmartin, D.J. Literature review and proposal of best practice for ophthalmologists: Monitoring of patients following intravitreal brolucizumab therapy. Ir. J. Med. Sci. 2023, 192, 447–456. [Google Scholar] [CrossRef] [PubMed]
- Monés, J.; Srivastava, S.K.; Jaffe, G.J.; Tadayoni, R.; Albini, T.A.; Kaiser, P.K.; Holz, F.G.; Korobelnik, J.F.; Kim, I.K.; Pruente, C.; et al. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology 2021, 128, 1050–1059. [Google Scholar] [CrossRef]
- Khanani, A.M.; Brown, D.M.; Jaffe, G.J.; Wykoff, C.C.; Adiguzel, E.; Wong, R.; Meng, X.; Heier, J.S.; Merlin Investigators. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology 2022, 129, 974–985. [Google Scholar] [CrossRef]
- Inoda, S.; Takahashi, H.; Maruyama-Inoue, M.; Ikeda, S.; Sekiryu, T.; Itagaki, K.; Matsumoto, H.; Mukai, R.; Nagai, Y.; Ohnaka, M.; et al. Incidence and risk factors of intraocular inflammation after brolucizumab treatment in Japan: A Multicenter Age-Related Macular Degeneration Study. Retina 2024, 44, 714–722. [Google Scholar]
- Soliman, M.K.; Gini, G.; Kuhn, F.; Parolini, B.; Ozdek, S.; Adelman, R.A.; Sallam, A.B. Visual outcome of early vitrectomy and intravitreal antibiotics in acute postsurgical and postintravitreal injection endophthalmitis: European Vitreo-Retinal Society Endophthalmitis Study Report Two. Retina 2021, 41, 423–430. [Google Scholar] [CrossRef]
- Campos, A. Correspondence. Retina 2022, 42, e8–e9. [Google Scholar] [CrossRef]
- Negretti, G.S.; Chan, W.; Pavesio, C.; Muqit, M.M.K. Vitrectomy for endophthalmitis: 5-year study of outcomes and complications. BMJ Open Ophthalmol. 2020, 5, e000423. [Google Scholar] [CrossRef] [PubMed]
- Grzybowski, A.; Told, R.; Sacu, S.; Bandello, F.; Moisseiev, E.; Loewenstein, A.; Schmidt-Erfurth, U.; Euretina Board. 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica 2018, 239, 181–193. [Google Scholar] [CrossRef] [PubMed]
- Bhavsar, A.R.; Glassman, A.R.; Stockdale, C.R.; Jampol, L.M.; Diabetic Retinopathy Clinical Research Network. Elimination of Topical Antibiotics for Intravitreous Injections and the Importance of Using Povidone-Iodine: Update From the Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol. 2016, 134, 1181–1183. [Google Scholar] [CrossRef]
- Soundararajan, S.; Robbins, C.B.; Feng, H.L.; Fekrat, S. Management Patterns and Outcomes for Intravitreal Injection-Related Endophthalmitis. J. Vitreoretin. Dis. 2022, 6, 188–193. [Google Scholar] [CrossRef] [PubMed]
- Israilevich, R.N.; Mansour, H.; Patel, S.N.; Garg, S.J.; Klufas, M.A.; Yonekawa, Y.; Regillo, C.D.; Hsu, J. Risk of Endophthalmitis Based on Cumulative Number of Anti-VEGF Intravitreal Injections. Ophthalmology 2024, 131, 667–673. [Google Scholar] [CrossRef]
- Shimada, H.; Hattori, T.; Mori, R.; Nakashizuka, H.; Fujita, K.; Yuzawa, M. Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch. Clin. Exp. Ophthalmol. 2013, 251, 1885–1890. [Google Scholar] [CrossRef]
- Levinson, J.D.; Garfinkel, R.A.; Berinstein, D.M.; Flory, M.; Spellman, F.A. Timing of Povidone-Iodine Application to Reduce the Risk of Endophthalmitis after Intravitreal Injections. Ophthalmol. Retin. 2018, 2, 654–658. [Google Scholar] [CrossRef]
- Campos, A.; Caramelo, F.; do Carmo, A. RE: Hsu J: Minimizing the Risk of Endophthalmitis after Injection. What Have We Learned? (Ophthalmol Retina. 2019;3:1–2). Ophthalmol Retin. 2019, 3, e3–e4. [Google Scholar] [CrossRef]
- Brown, D.M.; Emanuelli, A.; Bandello, F.; Barranco, J.J.E.; Figueira, J.; Souied, E.; Wolf, S.; Gupta, V.; Ngah, N.F.; Liew, G.; et al. KESTREL and KITE: 52-Week Results from Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am. J. Ophthalmol. 2022, 238, 157–172. [Google Scholar] [CrossRef]
- Haug, S.J.; Hien, D.L.; Uludag, G.; Ngoc, T.T.T.; Lajevardi, S.; Halim, M.S.; Sepah, Y.J.; Do, D.V.; Khanani, A.M. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am. J. Ophthalmol. Case Rep. 2020, 18, 100680. [Google Scholar] [CrossRef]
- Igwe, F.; Lodha, A.; Ravindran, A. Trends in the Cumulative Post-Marketing Reporting Rates of Retinal Vasculitis and/or Retinal Vascular Occlusion and Associated Vision Loss with Brolucizumab. Ophthalmol. Ther. 2023, 12, 593–598. [Google Scholar] [CrossRef] [PubMed]
- Yeom, H.; Kwon, H.J.; Kim, Y.J.; Lee, J.; Yoon, Y.H.; Lee, J.Y. Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration. Sci. Rep. 2023, 13, 11400. [Google Scholar] [CrossRef]
- Bodaghi, B.; Souied, E.H.; Tadayoni, R.; Weber, M.; Ponthieux, A.; Kodjikian, L. Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmol. Retin. 2023, 7, 879–891. [Google Scholar] [CrossRef] [PubMed]
- Khanani, A.M.; Zarbin, M.A.; Barakat, M.R.; Albini, T.A.; Kaiser, P.K.; Guruprasad, B.; Agashivala, N.; Justin, S.Y.; Wykoff, C.C.; MacCumber, M.W. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. JAMA Ophthalmol. 2022, 140, 20–28. [Google Scholar] [CrossRef]
- Dugel, P.U.; Singh, R.P.; Koh, A.; Ogura, Y.; Weissgerber, G.; Gedif, K.; Jaffe, G.J.; Tadayoni, R.; Schmidt-Erfurth, U.; Holz, F.G. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2021, 128, 89–99. [Google Scholar] [CrossRef]
- Bodaghi, B.; Khanani, A.M.; Khoramnia, R.; Pavesio, C.; Nguyen, Q.D. Gains in the current understanding of managing neovascular AMD with brolucizumab. J. Ophthalmic Inflamm. Infect. 2023, 13, 51. [Google Scholar] [CrossRef] [PubMed]
- Heier, J.S.; Khanani, A.M.; Ruiz, C.Q.; Basu, K.; Ferrone, P.J.; Brittain, C.; Figueroa, M.S.; Lin, H.; Holz, F.G.; Patel, V.; et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. Lancet 2022, 399, 729–740. [Google Scholar] [CrossRef] [PubMed]
- Sivaprasad, S.; Leal, S.; Machewitz, T.; Zhang, X. Subgroup analyses from the Phase 3 PULSAR trial of aflibercept 8 mg in patients with treatment-naïve neovascular age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2023, 64, 2238. [Google Scholar]
Age (yo) | Gender | Eye | Date of Onset of Symptoms (Month.Year) | Duration of Symptoms until Assistance | Elapsed Time since the Injection | Findings at Presentation | BCVA at Onset of Symptoms (and Letter Loss) | Number of BRO Injection | Therapy | Time to Discharge | Final BCVA | Disease | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient 1 | 68 | Female | RE | 8.2022 | 24 days | 21 days | Floatters Vitritis | 46 L (−6L ) (≈20/120) | first | Topical and systemic steroids | 4 weeks | 52L (20/87) | PCV |
Patient 2 | 84 | Female | RE | 5.2022 | 07 days | 07 days | Floatters Keratic precipitates Tyndall 1+ | 70 L (+4 L) (20/40) | third | Topical steroids | 2 weeks | 70L (20/40) | nAMD |
Patient 3 | 62 | Male | RE | 11.2022 | immediate | 21 days | Keratic precipitates Tyndall 1+ Mild vitritis | 73L(−12 L) (≈20/35) | first | Subtenon triamcinolone Topical and systemic steroids | 4 weeks | 85L (20/20) | PCV |
Patient 4 | 70 | Male | LE | 3.2023 | 47 days | 7 days | Pain Redness Hyperemia and ciliary congestion Vasculitis Arterial occlusion Retinal and macular ischemia | CF (−72 L) | second | Dexametasone implant Topical and systemic steroids | 9 weeks | 32L (≈20/ 230) | PCV |
Condition | Events | Observations | General Incidence (%) | P |
---|---|---|---|---|
A (aflibercept) | 2 | 2884 | 0.00048 | 0.403 |
B (brolucizumab) | 4 | 468 | 0.00048 | <0.001 |
Condition A | ||||||||
N | 6250 | 12,000 | 18,000 | 24,000 | 30,000 | 36,000 | 42,000 | 48,000 |
p | 0.598 | 0.635 | 0.643 | 0.647 | 0.638 | 0.642 | 0.645 | 0.646 |
OR | 2.33 | 1.58 | 1.50 | 1.46 | 1.56 | 1.53 | 1.51 | 1.49 |
Condition B | ||||||||
N | 10,500 | 20,000 | 30,000 | 40,000 | 50,000 | 60,000 | 70,000 | 80,000 |
p | <0.001 | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
OR | 86.20 | 26.03 | 25.45 | 22.71 | 21.33 | 20.51 | 19.96 | 20.15 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Campos, A.; Mota, C.; Caramelo, F.; Oliveira, N.; Silva, S.; Sousa, J. Inflammation and Vasculitis Related to Brolucizumab. J. Clin. Med. 2024, 13, 5208. https://doi.org/10.3390/jcm13175208
Campos A, Mota C, Caramelo F, Oliveira N, Silva S, Sousa J. Inflammation and Vasculitis Related to Brolucizumab. Journal of Clinical Medicine. 2024; 13(17):5208. https://doi.org/10.3390/jcm13175208
Chicago/Turabian StyleCampos, António, Carolina Mota, Francisco Caramelo, Nuno Oliveira, Sara Silva, and João Sousa. 2024. "Inflammation and Vasculitis Related to Brolucizumab" Journal of Clinical Medicine 13, no. 17: 5208. https://doi.org/10.3390/jcm13175208